Fabry nephropathy as the clinical anchor for kidney-centered metabolic surveillance: linking genetic heterogeneity to early risk identification. [PDF]
Xie Y, Zhong J.
europepmc +1 more source
From diagnosis to disease-specific treatment: first experience with enzyme replacement therapy for Fabry disease in North Macedonia-a case series. [PDF]
Karanfilovski V +6 more
europepmc +1 more source
The quiet reservoir: Understanding Shiga toxin Escherichia coli O157:H7 colonization in cattle. [PDF]
Feldmann KP, Myer PR.
europepmc +1 more source
Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy. [PDF]
Li Y +8 more
europepmc +1 more source
Effects of Catfish Egg Lectin on Cancer Cells Differ According to the Globotriaosylceramide Species They Express. [PDF]
Sugawara S +4 more
europepmc +1 more source
Molecular, Metabolic and Inflammatory Patterns Involved in Pathogenesis of Anderson-Fabry Disease. [PDF]
Simonetta I, Baglio I, Tuttolomondo A.
europepmc +1 more source
A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease. [PDF]
Ren H +14 more
europepmc +1 more source
Shiga toxin delivery in extracellular vesicles induces high mortality and severe kidney injury in a Gb3-dependent manner. [PDF]
Wendler M +6 more
europepmc +1 more source
Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series. [PDF]
He Z, Wu Y, Yang H, Li Y, Xu L.
europepmc +1 more source
Persistent Hematuria and Proteinuria in a Patient with SLE Nephritis. [PDF]
Singh T, Panzer SE, Garg S.
europepmc +1 more source

